The future of European Cancer Centres

The May Molecular Oncology issue is out with a policy article on the attributes, hallmarks and performance of Cancer Centres and Comprehensive Cancer Centres in Europe
The future of European Cancer Centres
Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

The increasing incidence of cancer worldwide has an enormous impact on society and on the health care system. High quality cancer care is of utmost importance in combating the cancer ‘epidemics’ both locally and globally. In the Policy article published in the May Molecular Oncology issue; Sebastian Kehrloesser, Simon Oberst and colleagues analyse the attributes of European Cancer Centres (CCs) in order to identify existing inequalities across European countries and provide recommendations about how these may be resolved in the context of the EU Cancer Mission and Europe’s Beating Cancer Plan. Analysis of quantitative and qualitative data from 40 large European CCs demonstrated high standards of patient care, multidisciplinarity, and patient-centeredness in all accredited Comprehensive Cancer Centres (CCCs) and CCs. However, CCCs performed better than CCs in translational research, clinical trials and innovation. The data additionally revealed a variation in leadership- and management-related quality standards and outlined the importance of effective governance of CCs.

Join the FEBS Network today

Joining the FEBS Network’s molecular life sciences community enables you to access special content on the site, present your profile, 'follow' contributors, 'comment' on and 'like' content, post your own content, and set up a tailored email digest for updates.